Data back first-line use of Novartis’ eltrombopag in SAA
Novartis has announced the publication of data showing high response rates in patients with the rare blood disorder severe aplastic anaemia (SAA) taking its medicine eltrombopag, supporting its first-line use for the condition.
Read More
